Bubendorf, Switzerland, Tuesday, January 24, 2023 – CIS Pharma engages additional resources in 2023 to develop a novel linker/carrier system to conjugate ASO and siRNA for targeted delivery. To widen the therapeutic use of oligonucleotides, CIS Pharma is developing technology for bio-conjugation of RNAi to targeting moieties, similar to the targeting technology developed for cancer therapies. The conjugate allows gene-modifying oligonucleotides to silence the mRNA of the protein of interest in selected and targeted cells. The design is based on the carrier technology that was successfully tested in a biodistribution study and as a carrier for  a cytotoxic drug against cancer. The polymer carrier is optimized in size and charge for the delivery of ASO and siRNA and different conjugation strategies are being tested.


About CIS Pharma linker and carrier technology for targeted delivery of RNAi

RNA interference (RNAi) is a mechanism used to defend against external invasion. Oligo- and poly-nucleotide based RNAi therapeutics comprise a high clinical potential for unmet medical diseases and are seen as promising approach to combat a number of different indications including oncology, genetic disorders, auto-immune disorders, orphan diseases and viral infections.

Without a targeting technology, the therapeutics are predominantly metabolized by the liver. To prevent metabolization, the oligo-nucleotides are applied locally, limiting the clinical window for oligonucleotide therapies. Alternatively, targeted delivery to specific cells has to be developed to create novel therapies.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of therapeutics that are the standard of care, thereby improving patient’s experience and treatment outcome. Medical need, patient centricity and digital technology are key to our research and development programs. CIS Pharma is located in the region of Basel, Switzerland, one of the most successful life sciences locations in the world. For more information about the company, visit our website www.cis-pharma.com.